-
公开(公告)号：EP4225208A1
公开(公告)日：2023-08-16
申请号：EP20811087.4
申请日：2020-10-06
申请人： Université d'Aix Marseille , Assistance Publique - Hôpitaux de Marseille , Université Gustave Eiffel
发明人： ALIMI, Yves
-
公开(公告)号：EP4189689A1
公开(公告)日：2023-06-07
申请号：EP21758074.5
申请日：2021-08-02
发明人： FINA, Frédéric , BIANCOTTO, Alain , PELLEGRINO, Eric , DELAVEAU, Maéva , MACAGNO, Nicolas , FIGARELLA-BRANGER, Dominique
IPC分类号： G16B50/40
-
公开(公告)号：EP4168054A1
公开(公告)日：2023-04-26
申请号：EP21732341.9
申请日：2021-06-18
申请人： Universite d'Aix Marseille , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM , Assistance Publique Hôpitaux de Marseille
发明人： GUILLET, Benjamin , BOUHLEL, Ahlem , MOYON, Anaïs , LOUIS, Béatrice, Marie, Florence , DIGNAT-GEORGE, Françoise , BALASSE, Laure , GARRIGUE, Philippe , FERNANDEZ, Samantha
IPC分类号： A61K51/08
-
公开(公告)号：EP3784342A2
公开(公告)日：2021-03-03
申请号：EP19791449.2
申请日：2019-04-16
申请人： Université d'Aix Marseille , Centre National de la Recherche Scientifique , Ecole Centrale De Marseille (ECM) , Assistance Publique Hôpitaux de Marseille , Multiwave Technologies AG
-
公开(公告)号：EP3224626A1
公开(公告)日：2017-10-04
申请号：EP15805310.8
申请日：2015-11-26
申请人： Université d'Aix Marseille , Assistance Publique Hôpitaux de Marseille , Institut National de la Santé et de la Recherche Médicale (INSERM)
发明人： RUF, Jean , GUIEU, Régis , PAGANELLI, Franck , BONELLO, Laurent , MOTTOLA, Giovanna , KIPSON, Nathalie
CPC分类号： G01N33/74 , C07K16/286 , C07K16/2869 , C07K2317/75 , G01N33/6893 , G01N2333/726 , G01N2800/324 , G01N2800/52
摘要： The invention relates to a method of diagnosis or prognosis of an obliterative arteriopathy in a subject, comprising determining the expression level of adenosine A 2A receptors expressed at the cell surface of peripheral blood mononuclear cells obtained from said subject. The invention also relates to an agonist-like monoclonal antibody directed to the human adenosine A 2A receptor, useful for carrying out this method.
摘要翻译： 本发明涉及诊断或预后对象中闭塞性动脉病的方法，包括确定从所述对象获得的外周血单核细胞的细胞表面处表达的腺苷A 2A受体的表达水平。 本发明还涉及用于实施该方法的针对人类腺苷A 2A受体的激动剂样单克隆抗体。
-
公开(公告)号：EP2875356A1
公开(公告)日：2015-05-27
申请号：EP13744473.3
申请日：2013-07-23
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , Université d'Aix Marseille , Assistance Publique Hôpitaux de Marseille
IPC分类号： G01N33/564 , G01N33/68
CPC分类号： G01N33/6803 , G01N33/564 , G01N33/6854 , G01N2800/101 , G01N2800/20 , G01N2800/24
摘要： The present invention relates to an in vitro method for diagnosing scleroderma in a subject, said method comprising the step of detecting in a biological sample obtained from the subject one or more autoantibodies recognizing one or more protein biomarkers selected from the group of proteins consisting of THEXl, AIFl, FGF2, EphB2, CLK1 and ANKS6.
-
公开(公告)号：EP2636033A1
公开(公告)日：2013-09-11
申请号：EP11784419.1
申请日：2011-11-02
CPC分类号： G09B23/288 , G09B23/285 , G09B23/30
摘要： The invention relates to a simulator for learning tracheal intubation, including: an anatomical dummy element (1) reproducing at least one oral cavity (2) provided with a tongue (4), an epiglottis (7), and the corresponding glossoepiglottic fold (8); and a simulation system (15) capable of determining at least one physiological parameter of a patient subjected to a tracheal intubation. Said simulator comprises: at least one force sensor (13) arranged on the dummy element at the glossoepiglottic fold so as to measure the force applied at this point by the blade (11) of a laryngoscope (12) handled by the operator; and transmission means (14) for providing the value of the measurement performed by said force sensor at the input of said simulation system, wherein the simulation system is arranged so as to take said value of the measurement performed by the force sensor into account for determining said physiological parameter.
-
8.发明授权
公开(公告)号：EP2150623B8
公开(公告)日：2012-12-19
申请号：EP08805655.1
申请日：2008-06-06
-
公开(公告)号：EP2187868A1
公开(公告)日：2010-05-26
申请号：EP08804068.8
申请日：2008-09-11
CPC分类号： A61K9/127 , A61K9/00 , A61K9/1277 , A61K9/1278 , A61K31/513 , A61K31/7076 , A61K45/06 , A61K2300/00
摘要： The invention provides a pharmaceutical composition comprising liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino). In a preferred embodiment, the liposomes comprise phosphatidylcholine (PC), phosphatidyl-glycol (PG) and sterol, preferably in a molar ratio PC/PG/sterol of 20-80/10-60/15-60. The invention further provides a method for preparing liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino), and the use thereof for the manufacture of a medicament for treating cancer in a patient.
-
公开(公告)号：EP4319685A1
公开(公告)日：2024-02-14
申请号：EP22721034.1
申请日：2022-04-06
-
-
-
-
-
-
-
-
-
搜索结果
80 条记录 (耗时 0.017 秒)
